Endocyte (ECYT) Reports FDA Acceptance of Radiographic Progression Free Survival as Alternative Primary Endpoint of VISION Trial
Tweet Send to a Friend
Endocyte, Inc. (NASDAQ: ECYT) today announced that following a meeting with the U.S. Food and Drug Administration (FDA), it was ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
